

[Open Peer Review on Qeios](#)

# Gilteritinib

National Cancer Institute

## Source

National Cancer Institute. *Gilteritinib*. NCI Thesaurus. Code C116722.

An orally bioavailable inhibitor of the receptor tyrosine kinases (RT Ks) FMS-related tyrosine kinase 3 (FLT 3, ST K1, or FLK2), AXL (UFO or JT K11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT 3, AXL and ALK. This may result in an inhibition of FLT 3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RT Ks. FLT 3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.